GlassScriptPhysician profile
Jayasree Grandhi
NPI 1912933177
$1,916.89
in general payments reported to CMS, 2019-2025
21 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.86 · 2021: $19.69 · 2022: $423 · 2023: $389 · 2024: $466 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432 · Education: $7.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.21 |
| Education | $7.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $398.88 | 2024-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $193.22 | 2022-2025 | Farxiga |
| Aurinia Pharma U.S., INC. | $181.51 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $160.57 | 2022-2024 | Benlysta |
| Horizon Therapeutics Plc | $134.14 | 2022-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $119.62 | 2024 | Nxstage System One, Velphoro |
| Abbott Laboratories | $106.66 | 2023 | Mitraclip |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.65 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $92.17 | 2022-2025 | Jynarque |
| Novo Nordisk INC | $76.15 | 2020-2025 | Ozempic, Rybelsus |
| Nxstage Medical, INC. | $74.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $65.49 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.83 | 2022 | |
| Travere Therapeutics, INC. | $37.14 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $28.40 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $24.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.85 | 2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $20.69 | 2020 | |
| Opko Pharmaceuticals, LLC | $15.26 | 2025 | Rayaldee |
| Ardelyx, INC. | $15.05 | 2024 | Ibsrela |
| Boston Scientific Corporation | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayasree Grandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.